⌕

Biogen (BIIB) vs Teva- Pharmaceutical Industries (TEVA)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
52
Biogen Inc
$253.40 · $37B · as of last close

The front-runner. Leads the balanced score. Its widest win over the field is balance sheet.

#2 FIT
48
Teva- Pharmaceutical Industries Ltd.
$44.50 · $52B · as of last close
Street favorite
of the stocks compared here

The challenger. Trails the leader on the balanced score. Its widest win over the field is growth.

BIIB barely leads (52/100 vs TEVA 48) under a balanced style, mostly on balance sheet. But TEVA wins on growth, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorBIIBTEVA
Overall fit score
weighted for your balanced goal
✓ 52
48
5 of 8 factors known
Valuation
Cheaper for what you get
1×
✓ P/E 108 · EV/EBITDA 23.1
P/E trailing
40
P/E 104 · EV/EBITDA 26.7
P/E trailing
23
Growth
Revenue & earnings momentum
1×
—
31
✓ —
51
Profitability & quality
Margins & return on capital
1×
✓ Net 3% · ROIC 1%
TTM through Sep 30, 2026
57
✓ Net 3% · ROIC 6%
TTM through Sep 30, 2026
57
Total return
Share-price change with dividends reinvested
1×
✓ 5Y −2%/yr
45
—
—
Risk (calm = better)
Volatility & drawdown
1×
✓ β 0.5 · DD −64%
76
β —
—
Balance sheet†
Debt vs cash cushion
1×
✓ Net debt/EBITDA 3.4×
TTM through Sep 30, 2026
29
Net debt/EBITDA 5.2×
TTM through Sep 30, 2026
7
Dividend & income
Cash paid to you
1×
✓ —
40
—
—
Analyst sentiment
Forward EPS growth (consensus)
1×
Est EPS +30%/yr · 20 analysts
95
✓ Est EPS +52%/yr · 9 analysts
100
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQuality
Return & Safety & Income axis omitted: no data for one of these stocks.
■ BIIB■ TEVA
CAN YOU STOMACH THE RIDE?
Worst drawdown3-year beta vs S&P 500VolatilityHistory
BIIB−64%0.5435%5Y
TEVA———0.1Y
Drawdown and volatility are measured over five years on the same total return as the chart, dividends reinvested.
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Best factor is analyst sentiment: Est EPS +30%/yr · 20 analysts (score 95).

BEAR CASE

▼ Weakest on growth: — (score 31).

▼ Weakest on analyst sentiment: Est EPS +30%/yr · 20 analysts (score 95).

BULL CASE

▲ Leads on analyst sentiment: Est EPS +52%/yr · 9 analysts (score 100).

BEAR CASE

▼ Weakest on balance sheet (score 7). Net debt/EBITDA 5.2× is one of the 5 inputs.

▼ Weakest on valuation: P/E 104 · EV/EBITDA 26.7 (score 23).

WHAT COULD CHANGE THE SCORE
Balance sheetCurrently 29/100 (Net debt/EBITDA 3.4×). Taking it to 100 would lift the balanced score by 9 points, the biggest single move available.
GrowthCurrently 31/100 (—). Taking it to 100 would lift the balanced score by 8 points, the next biggest.
Balance sheetCurrently 7/100 (Net debt/EBITDA 5.2×). Taking it to 100 would lift the balanced score by 18 points, the biggest single move available.
ValuationCurrently 23/100 (P/E 104 · EV/EBITDA 26.7). Taking it to 100 would lift the balanced score by 15 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 13, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.